newsfilter
← Latest News
GlobeNewswire·

CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates

  • CG Oncology reported third-quarter 2026 financial results & provided business updates on November 6, 2026.
  • PIVOT-006 Phase 3 topline data for cretostimogene monotherapy in intermediate-risk & high-grade Ta NMIBC is anticipated in November 2026.
  • 12-month data for BOND-003 Cohort P & CORE-008 Cohort CX is anticipated in December 2026.
  • The BLA submission for BCG-unresponsive NMIBC is anticipated in Q4 2026.
  • The company appointed Isabel Kalofonos as Chief Commercial Officer in October 2026.
  • Cash, cash equivalents, & marketable securities totaled $984.5 million as of September 30, 2026, sufficient to fund operations through 2029.
  • Research & development expenses were $39.2 million for the quarter, driven by increased clinical trial & compensation costs.
  • General & administrative expenses were $23.0 million for the quarter, primarily due to reduced professional fees offset by higher personnel costs.
  • The net loss for the third quarter was $56.9 million, or $(0.64) per share, compared to a net loss of $43.8 million in the prior year period.
  • Cretostimogene has received FDA Fast Track & Breakthrough Therapy designations for BCG-unresponsive NMIBC.
Company
CG Oncology Inc.
Keywords
Nasdaq:CGON, CG Oncology Inc.